According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Highlighted text has been updated as of December 20, 2024. The SURMOUNT-1 trial showed that among patients with obesity, once-weekly tirzepatide reduced body weight substantially as compared to ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Rohit Sharma supports Virat Kohli amid struggles in Australia, citing Kohli's caliber as a player. While Kohli's chase of off ...

Surmount Logistics, Chennai being a startup company incorporated only in the year 2022, strongly believe that their employees ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...